1. Detection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry[S]
- Author
-
Swati Anand, SydneyA. Young, M. Sean Esplin, Benjamin Peaden, H. Dennis Tolley, T. Flint Porter, Michael W. Varner, Mary E. D'Alton, Bruce J. Jackson, and Steven W. Graves
- Subjects
diagnosis ,lipidomics ,pregnancy ,mass spectrometer ,lipids ,Biochemistry ,QD415-436 - Abstract
Despite substantial research, the early diagnosis of preeclampsia remains elusive. Lipids are now recognized to be involved in regulation and pathophysiology of some disease. Shotgun lipidomic studies were undertaken to determine whether serum lipid biomarkers exist that predict preeclampsia later in the same in pregnancy. A discovery study was performed using sera collected at 12–14 weeks pregnancy from 27 controls with uncomplicated pregnancies and 29 cases that later developed preeclampsia. Lipids were extracted and analyzed by direct infusion into a TOF mass spectrometer. MS signals, demonstrating apparent differences were selected, their abundances determined, and statistical differences tested. Statistically significant lipid markers were reevaluated in a second confirmatory study having 43 controls and 37 preeclampsia cases. Multi-marker combinations were developed using those lipid biomarkers confirmed in the second study. The initial study detected 45 potential preeclampsia markers. Of these, 23 markers continued to be statistically significant in the second confirmatory set. Most of these markers, representing several lipid classes, were chemically characterized, typically providing lipid class and potential molecular components using MS2. Several multi-marker panels with areas under the curve >0.85 and high predictive values were developed. Developed panels of serum lipidomic biomarkers appear to be able to identify most women at risk for preeclampsia in a given pregnancy at 12–14 weeks gestation.
- Published
- 2016
- Full Text
- View/download PDF